Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2009 2
2010 2
2011 2
2012 2
2014 1
2016 1
2017 4
2018 5
2019 2
2020 4
2021 10
2022 7
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Maurer MS, et al. Among authors: sultan mb. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27. N Engl J Med. 2018. PMID: 30145929 Free article. Clinical Trial.
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Damy T, et al. Among authors: sultan mb. Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12. Eur J Heart Fail. 2021. PMID: 33070419 Free PMC article. Clinical Trial.
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ. Elliott P, et al. Among authors: sultan mb. Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20. Circ Heart Fail. 2022. PMID: 34923848 Free PMC article.
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Rapezzi C, et al. Among authors: sultan mb. JACC Heart Fail. 2021 Feb;9(2):115-123. doi: 10.1016/j.jchf.2020.09.011. Epub 2020 Dec 9. JACC Heart Fail. 2021. PMID: 33309574 Free article.
Reply: Bio-Profiling of Transthyretin Amyloid Cardiomyopathy.
Rapezzi C, Sultan MB, Maurer MS. Rapezzi C, et al. Among authors: sultan mb. JACC Heart Fail. 2021 May;9(5):404. doi: 10.1016/j.jchf.2021.02.010. JACC Heart Fail. 2021. PMID: 33926735 Free article. No abstract available.
Tafamidis for Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Sultan MB, Rapezzi C. Maurer MS, et al. Among authors: sultan mb. N Engl J Med. 2019 Jan 10;380(2):196-197. doi: 10.1056/NEJMc1814074. N Engl J Med. 2019. PMID: 30625051 No abstract available.
44 results